DaVita Inc. (DVA)
DaVita misses quarterly profit estimates on rising costs, lower volumes
DaVita missed Wall Street estimates for third-quarter profit on Wednesday, as the kidney dialysis provider grappled with rising patient care costs and declining treatment volumes.
Can Technology and Cost Discipline Lift DaVita's Q3 Earnings?
DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $127.89, denoting a -2.4% move from the preceding trading day.
DaVita HealthCare (DVA) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DaVita HealthCare (DVA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, DaVita HealthCare (DVA) closed at $128, marking a -1.62% move from the previous day.
Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DaVita HealthCare (DVA) Stock Drops Despite Market Gains: Important Facts to Note
DaVita HealthCare (DVA) closed at $132.26 in the latest trading session, marking a -3.26% move from the prior day.
DaVita: Aggressive Buybacks Despite Rising Cost Of Debt
DaVita has reduced the share count by over 10% in the last six months, but interest expenses increased by 50% Y/Y. International revenues grew by 36% Y/Y, and DaVita is pending regulatory approval to close an acquisition from Fresenius Medical Care AG in Brazil. In the U.S., volumes declined by 1.1% Y/Y during Q2 2025 due to missed treatments caused by the severe flu season and the April cyber attack.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Investors Undervaluing DaVita (DVA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.
